Dual Drug Combinations Show Promise in Overcoming Multiple Myeloma Resistance
Key Insights
Bedaquiline, an FDA-approved antimycobacterial drug, significantly amplifies carfilzomib's cytotoxic effects in both proteasome inhibitor-sensitive and resistant multiple myeloma (search) cells by targeting mitochondrial ATP synthase.
VS-4718, a dual FAK (search)/PYK2 (search) inhibitor, enables dramatic reduction of carfilzomib doses while maintaining therapeutic efficacy and successfully overcomes resistance in PSMB5 (search)-mutated triple-resistant myeloma cells.
Both combination strategies demonstrate selective toxicity toward cancer cells while sparing normal cells, offering potential solutions for fragile patients and those with treatment-resistant disease.
Two independent research studies have identified promising drug combination strategies that could transform treatment approaches for multiple myeloma (search) (MM), particularly in addressing the critical challenges of proteasome inhibitor resistance and dose-limiting toxicities.
Bedaquiline Enhances Proteasome Inhibitor Efficacy
Researchers conducted a comprehensive small-molecule chemical screen in the presence of carfilzomib (CFZ) and discovered that bedaquiline (BDQ), an FDA-approved antimycobacterial agent, acts as a potent synergistic partner. The study demonstrated that BDQ and its fumarate salt (BDQ-F) significantly amplified CFZ-induced cytotoxicity in both PI-sensitive and PI-resistant MM cells, as well as in AL amyloidosis (search) and other B-cell malignancies, while showing minimal toxicity toward normal cells.
Mechanistic investigations revealed that BDQ specifically targets the ATP5F1C (search) subunit of mitochondrial ATP synthase. The BDQ-CFZ combination triggered extensive apoptosis by exacerbating proteotoxic stress and enhancing proteasome-associated pathways. Notably, BDQ specifically enhanced CFZ's inhibition of the proteasome's chymotrypsin-like activity and demonstrated synergy with multiple proteasome and ubiquitin-activating enzyme inhibitors, but not with other standard MM agents, highlighting its selective interaction with the ubiquitin-proteasome system (UPS) pathway.
The therapeutic potential was validated in preclinical models, where BDQ-CFZ co-treatment markedly reduced MM cell viability and tumor burden in both patient-derived cells and zebrafish xenograft models.
VS-4718 Overcomes Carfilzomib Resistance
A parallel investigation examined VS-4718, a dual focal adhesion kinase (FAK (search)) and protein tyrosine kinase 2 beta (PYK2 (search)) inhibitor, in combination with carfilzomib across seven MM cell lines with diverse genetic backgrounds. The study found that 1 μM VS-4718 was sufficient to distinctively reduce metabolism and viability in all tested MM cell lines, with concentrations of 2 μM reducing viability by more than 50%.
The combination approach yielded remarkable results in dose reduction strategies. Treatment with 3 μM VS-4718 combined with minimal carfilzomib doses (3 nM in L-363 cells and 1.5 nM in MM.1S cells) achieved 70-80% reduction in cell survival. These carfilzomib concentrations, which had minimal impact when used alone, became highly effective in combination with VS-4718.
Overcoming Treatment Resistance
Perhaps most significantly, VS-4718 successfully overcame resistance in PSMB5 (search)-mutated, proteasome inhibitor triple-resistant MM cells. In L-363R350Ixa cells harboring heterozygous PSMB5 mutations, the combination of VS-4718 and 6 nM carfilzomib led to approximately 45% cell death, despite carfilzomib alone at this concentration reducing survival by only 5%. Similarly, in MM.1SR180Ixa cells with hemizygous PSMB5 mutations, the combination achieved 60% cell death, representing 25% more than simple additivity of the individual compounds.
Selective Toxicity Profile
Both combination strategies demonstrated favorable safety profiles. The BDQ-CFZ combination showed minimal toxicity toward normal cells, while VS-4718 at 3 μM had no significant impact on the survival of primary peripheral blood mononuclear cells (PBMCs) from healthy donors. When combined with carfilzomib, the combination reduced healthy cell survival by only 50%, compared to the 70-80% reduction observed in MM cells.
Clinical Implications
These findings address two major challenges in MM therapy: the inevitable development of proteasome inhibitor resistance and the dose-limiting toxicities associated with drugs like carfilzomib, particularly its cardiac toxicity. The ability to dramatically reduce carfilzomib doses while maintaining or enhancing therapeutic efficacy could be particularly valuable for fragile patients with relapsed/refractory MM who cannot tolerate high-dose treatments.
The research suggests that VS-4718's effectiveness appears independent of specific mutation profiles or PYK2 (search)/FAK (search) activation levels, potentially making it suitable for the highly heterogeneous MM patient population. Unlike targeted therapies limited to specific mutations, such as BRAF inhibitors for the approximately 4% of patients with BRAF V600E mutations, these combination approaches could benefit a broader patient population.
Both studies support the therapeutic potential of drug repurposing and combination strategies in overcoming treatment resistance in multiple myeloma (search), offering new avenues for patients who have exhausted standard treatment options.